Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca's Strong First Quarter Includes Significant Emerging Markets Growth

This article was originally published in PharmAsia News

Executive Summary

Having endured one major patent expiry in the past year and facing several others in the near future, AstraZeneca has turned in a number of directions to offset potential losses from big sellers like Pulmicort Respules, Nexium, Seroquel, andArimidex, often with mixed results

You may also be interested in...

AstraZeneca Outlines Branded Generics Strategy at Emerging Markets Event

AZ's emerging markets strategy includes selective entry into branded generics

AZ Taps India's Torrent to Add Branded Generics in Emerging Markets

Innovation-only AstraZeneca gets the branded generics religion, at least in emerging markets.

AZ Continues To Buy Pipeline With $100M Rigel Deal

Facing a raft of patent expiries, AstraZeneca pays richly for Rigel's Phase II oral RA candidate.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts